HomeAI · summaries
Storia in 2 fonti
Gossamer Bio Announces Up to $250 Million Structured Private Placement, Including $150 Million of Committed Capital, to Fund Seralutinib Through Potential FDA Approval
Gossamer Bio Announces Up to $250 Million Structured Private Placement, Including $150 Million of Committed Capital, to Fund Seralutinib Through Potential FDA Approval
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
morningstar.com
Gossamer Bio Announces Up to $250 Million Structured Private Placement, Including $150 Million of Committed Capital, to Fund Seralutinib…
Gossamer Bio Announces Up to $250 Million Structured Private Placement, Including $150 Million of Committed Capital, to Fund Seralutinib Through Potential FDA Approval
- ·
benzinga.com
Gossamer Bio Slips as $250M Financing Hinges on FDA Approval - Gossamer Bio (NASDAQ:GOSS)
Gossamer Bio Financing could provide up to $250 million, with much of the funding tied to seralutinib FDA milestones.